Overview
Metachromatic leukodystrophy (MLD), juvenile form, is a rare inherited metabolic disease that damages the protective covering (called myelin) around nerve cells in the brain and throughout the body. It is caused by a shortage of an enzyme called arylsulfatase A (ARSA), which is needed to break down certain fatty substances called sulfatides. When sulfatides build up, they destroy the myelin sheath, leading to progressive loss of brain and nerve function. The juvenile form of MLD typically begins between the ages of 3 and 16 years. Early signs often include declining school performance, behavioral changes, difficulty walking, and clumsiness. Over time, children may lose the ability to walk, talk, and care for themselves. Seizures, vision problems, and difficulty swallowing can also develop as the disease progresses. The treatment landscape for juvenile MLD has improved in recent years. In 2024, the FDA approved atidarsagene autotemcel (Lenmeldy), a gene therapy, for pre-symptomatic or early symptomatic patients. Hematopoietic stem cell transplantation (bone marrow transplant) may also be considered in early stages. However, once significant neurological damage has occurred, treatment options are mainly supportive, focusing on managing symptoms and maintaining quality of life. Early diagnosis is therefore critical to access potentially disease-modifying treatments.
Key symptoms:
Declining school performanceBehavioral and personality changesDifficulty walking and frequent fallsClumsiness and poor coordinationSlurred speechDifficulty swallowingMuscle stiffness or spasticitySeizuresVision lossLoss of ability to speakIncontinence (loss of bladder or bowel control)Progressive intellectual declinePeripheral neuropathy (numbness or tingling in hands and feet)Loss of ability to sit or hold head up
Clinical phenotype terms (37)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Juvenile
Begins in the teen years
Treatments
No FDA-approved treatments are currently listed for Metachromatic leukodystrophy, juvenile form.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Metachromatic leukodystrophy, juvenile form at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Metachromatic leukodystrophy, juvenile form.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Metachromatic leukodystrophy, juvenile form.
Community
No community posts yet. Be the first to share your experience with Metachromatic leukodystrophy, juvenile form.
Start the conversation →Latest news about Metachromatic leukodystrophy, juvenile form
No recent news articles for Metachromatic leukodystrophy, juvenile form.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage is my child's disease at, and does that affect which treatments are available?,Is my child a candidate for gene therapy (Lenmeldy) or bone marrow transplant?,How quickly should we expect the disease to progress, and what milestones should we watch for?,Should other family members or future pregnancies be tested for MLD?,What therapies and support services should we start now to maintain my child's abilities as long as possible?,Are there any clinical trials currently enrolling patients with juvenile MLD?,What is the plan for managing symptoms like seizures, spasticity, and swallowing difficulties as they develop?
Common questions about Metachromatic leukodystrophy, juvenile form
What is Metachromatic leukodystrophy, juvenile form?
Metachromatic leukodystrophy (MLD), juvenile form, is a rare inherited metabolic disease that damages the protective covering (called myelin) around nerve cells in the brain and throughout the body. It is caused by a shortage of an enzyme called arylsulfatase A (ARSA), which is needed to break down certain fatty substances called sulfatides. When sulfatides build up, they destroy the myelin sheath, leading to progressive loss of brain and nerve function. The juvenile form of MLD typically begins between the ages of 3 and 16 years. Early signs often include declining school performance, behavi
How is Metachromatic leukodystrophy, juvenile form inherited?
Metachromatic leukodystrophy, juvenile form follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Metachromatic leukodystrophy, juvenile form typically begin?
Typical onset of Metachromatic leukodystrophy, juvenile form is juvenile. Age of onset can vary across affected individuals.